Latest News about Joseph Schwartz
Recent news which mentions Joseph Schwartz
Sarepta Falls 50% To 10-Month Low After DMD Gene Therapy Study Misses Primary Endpoint
January 08, 2021
From Benzinga
From Business Journals
6 Gene Therapy M&A Targets On The Radar
March 27, 2019
From Benzinga
What's The Thesis On ProQR Now, After Promising Phase 1 Data?
September 26, 2017
From Benzinga
FDA Letter On Intercept Pharma Doesn't Include Black Box Warning Label...Yet
September 22, 2017
From Benzinga
?Why Sarepta’s latest trial data may presage another FDA controversy
September 06, 2017
From Business Journals
From Benzinga
Do Analysts See A Path Forward For Ophthotech's Fovista?
March 24, 2017
From Benzinga
From Benzinga
Sarepta Under Pressure Amid Concerning Exondys 51 Survey Results
February 01, 2017
From Benzinga
2 Opposing Views On The Future Of Sarepta
December 22, 2016
From Benzinga
From Benzinga
Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now
October 06, 2015
From Benzinga
Why Leerink Is Cutting Biogen Targets (But Still Bullish On The Stock)
September 15, 2015
Tickers
BIIB
From Benzinga
From Business Journals
UPDATE: Leerink Reiterates Outperform on BioMarin on Positive Cancer Drug Test Results
June 03, 2013
Tickers
BMRN
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.